JP2017513939A - 眼疾患および眼障害の治療のための方法および組成物 - Google Patents
眼疾患および眼障害の治療のための方法および組成物 Download PDFInfo
- Publication number
- JP2017513939A JP2017513939A JP2017504619A JP2017504619A JP2017513939A JP 2017513939 A JP2017513939 A JP 2017513939A JP 2017504619 A JP2017504619 A JP 2017504619A JP 2017504619 A JP2017504619 A JP 2017504619A JP 2017513939 A JP2017513939 A JP 2017513939A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- rhob
- composition
- compositions
- retinopathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本発明は、眼疾患の分野に関する。具体的には、本発明は、眼疾患、特に異常な血管新生を特徴とする眼疾患の治療のための新規の組成物および方法を提供する。
以下の定義は、本発明の理解を助けるために提供される:
単数形「a」、「an」、および「the」は、文脈が明らかにそうでないと指定しない限り複数形の参照対象を含む。
Claims (15)
- それを必要とする対象の眼疾患を治療または抑制する方法であって、前記対象に少なくとも1つの抗RhoB抗体または抗体断片を投与する工程を有する方法。
- 請求項1記載の方法であって、少なくとも1つの抗RhoB抗体または抗体断片と、少なくとも1つの薬学的に許容される担体とを有する組成物を投与する工程を有する方法。
- 請求項1記載の方法において、前記抗RhoB抗体または抗体断片は、配列ID番号:1に免疫学的に特異的である方法。
- 請求項1記載の方法において、前記抗RhoB抗体は7F7である方法。
- 請求項1記載の方法において、前記眼疾患は異常な血管新生を特徴とする方法。
- 請求項5記載の方法において、前記眼疾患は網膜症または黄斑変性症である方法。
- 請求項6記載の方法において、前記網膜症は未熟網膜症または糖尿病性網膜症である方法。
- 請求項6記載の方法において、前記黄斑変性症はウェット型黄斑変性症である方法。
- 請求項1記載の方法において、前記方法はレーザー療法または凍結療法を行う工程をさらに有する方法。
- 請求項1記載の方法において、前記方法は少なくとも1つの血管新生阻害剤を投与する工程をさらに有する方法。
- 請求項10記載の方法において、前記方法は血管内皮増殖因子阻害剤を投与する工程をさらに有する方法。
- 請求項11記載の方法において、前記血管内皮増殖因子阻害剤はラニズマブ(ranizumab)、ベバシズマブ、ペガプタニブ、およびアフィルベルセプト(afilbercept)からなる群から選択される方法。
- 少なくとも1つの抗RhoB抗体または抗体断片、少なくとも1つの血管新生阻害剤、および少なくとも1つの薬学的に許容される担体を有する組成物。
- 請求項13記載の組成物において、前記血管新生阻害剤は血管内皮増殖因子阻害剤である組成物。
- 請求項14記載の組成物において、前記血管内皮増殖因子阻害剤はラニズマブ(ranizumab)、ベバシズマブ、ペガプタニブ、およびアフィルベルセプト(afilbercept)からなる群から選択される組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461978061P | 2014-04-10 | 2014-04-10 | |
US61/978,061 | 2014-04-10 | ||
PCT/US2015/025322 WO2015157644A1 (en) | 2014-04-10 | 2015-04-10 | Methods and compositions for the treatment of ocular diseases and disorders |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017513939A true JP2017513939A (ja) | 2017-06-01 |
JP2017513939A5 JP2017513939A5 (ja) | 2018-05-10 |
JP6692795B2 JP6692795B2 (ja) | 2020-05-13 |
Family
ID=54288441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017504619A Active JP6692795B2 (ja) | 2014-04-10 | 2015-04-10 | 眼疾患および眼障害の治療のための方法および組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11447568B2 (ja) |
EP (1) | EP3129054B1 (ja) |
JP (1) | JP6692795B2 (ja) |
AU (1) | AU2015243261B2 (ja) |
CA (1) | CA2945149A1 (ja) |
WO (1) | WO2015157644A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013004551A1 (en) * | 2011-07-01 | 2013-01-10 | Bayer Intellectual Property Gmbh | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors |
WO2013023059A2 (en) * | 2011-08-10 | 2013-02-14 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of autoimmune and inflammatory diseases |
WO2013166449A2 (en) * | 2012-05-04 | 2013-11-07 | Acucela Inc. | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7795218B2 (en) | 2001-04-12 | 2010-09-14 | Bioaxone Therapeutique Inc. | ADP-ribosyl transferase fusion variant proteins |
US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
JP4200100B2 (ja) * | 2001-11-07 | 2008-12-24 | アジェンシス,インコーポレイテッド | 癌の処置および検出において有用な161p2f10bと称される、核酸および対応タンパク質 |
PT2470191E (pt) | 2009-08-24 | 2014-06-12 | Stealth Peptides Int Inc | Métodos e composições para prevenção ou tratamento de doenças oftálmicas |
US8759298B2 (en) | 2010-05-03 | 2014-06-24 | Scott & White Healthcare | Protein therapy for corneal inflammation, epithelial wound healing, and photoreceptor degeneration |
US20130123330A1 (en) | 2011-07-15 | 2013-05-16 | Patrick Y. Lu | Dual Targeted siRNA Therapeutics for Treatment of Diabetic Retinopathy and Other Ocular Neovascularization Diseases |
-
2015
- 2015-04-10 EP EP15776305.3A patent/EP3129054B1/en active Active
- 2015-04-10 US US15/302,088 patent/US11447568B2/en active Active
- 2015-04-10 JP JP2017504619A patent/JP6692795B2/ja active Active
- 2015-04-10 AU AU2015243261A patent/AU2015243261B2/en not_active Ceased
- 2015-04-10 CA CA2945149A patent/CA2945149A1/en active Pending
- 2015-04-10 WO PCT/US2015/025322 patent/WO2015157644A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013004551A1 (en) * | 2011-07-01 | 2013-01-10 | Bayer Intellectual Property Gmbh | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors |
WO2013023059A2 (en) * | 2011-08-10 | 2013-02-14 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of autoimmune and inflammatory diseases |
WO2013166449A2 (en) * | 2012-05-04 | 2013-11-07 | Acucela Inc. | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases |
Non-Patent Citations (1)
Title |
---|
PLOS ONE, 2011, VOL.6, ISSUE 2, E16979, P.1-13, JPN6018047794 * |
Also Published As
Publication number | Publication date |
---|---|
US20170190789A1 (en) | 2017-07-06 |
CA2945149A1 (en) | 2015-10-15 |
US11447568B2 (en) | 2022-09-20 |
WO2015157644A1 (en) | 2015-10-15 |
JP6692795B2 (ja) | 2020-05-13 |
EP3129054A1 (en) | 2017-02-15 |
EP3129054B1 (en) | 2020-12-09 |
AU2015243261B2 (en) | 2020-06-25 |
EP3129054A4 (en) | 2017-11-08 |
AU2015243261A1 (en) | 2016-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6395606B2 (ja) | 血液脳関門透過性の調節のためのセマフォリン−4d結合分子の使用 | |
JP2023515271A (ja) | ウイルス関連炎症を処置するための方法及び組成物 | |
KR102366682B1 (ko) | 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
JP5990511B2 (ja) | 血管新生に基づく眼障害の処置のための抗cd160特異的抗体 | |
WO2015109898A1 (zh) | VEGF与PDGFRβ双特异性融合蛋白及其用途 | |
CN110267985B (zh) | 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体 | |
JP2010509369A (ja) | 加齢黄斑変性症を処置するための方法 | |
JP2009533456A (ja) | 眼疾患処置のためのil−1抗体の使用 | |
JP7403553B2 (ja) | 眼科の疾患の個別化された治療 | |
KR20210071944A (ko) | 인플라마솜 관련 질환 또는 상태 치료용 조성물 및 방법 | |
US20240052038A1 (en) | Modified anti-PD-L1 Antibody and Methods and Uses for Treating a Neurodegenerative Disease | |
JP6863892B2 (ja) | 脳卒中を治療又は予防する方法 | |
JP5852968B2 (ja) | 上皮膜タンパク質2(emp2)結合試薬および眼疾患治療におけるその使用 | |
JP6692795B2 (ja) | 眼疾患および眼障害の治療のための方法および組成物 | |
JP2023532882A (ja) | レット症候群の処置のためのセマフォリン4d結合分子の使用 | |
CN109496218A (zh) | 用于治疗脊髓损伤和疼痛的抗反义导向分子a(rgma)拮抗性抗体 | |
WO2023108102A1 (en) | Anti-lcn-2 antibodies as a treatment for eye disorders | |
WO2024040232A2 (en) | Methods of treating conditions using anti-nmda receptor antibodies | |
KR20220092872A (ko) | 당뇨망막병증을 치료하기 위한 방법 및 조성물 | |
JP2024525990A (ja) | 単一ドメイン抗体によるブドウ膜炎の抑制 | |
WO2021220216A1 (en) | Methods for clearing vitreous hemorrhage | |
TW202126685A (zh) | 抗nrp1a抗體及其用於治療眼或眼部疾病之用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180323 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180323 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181204 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190301 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190430 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190604 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190820 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191115 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200225 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200319 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200415 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6692795 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |